Aemetis (NASDAQ:AMTX) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Aemetis (NASDAQ:AMTX - Get Free Report) had its price objective hoisted by analysts at Ascendiant Capital Markets from $19.00 to $20.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the specialty chemicals company's stock.

Other analysts also recently issued reports about the company. HC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Aemetis in a research report on Friday, March 14th. UBS Group cut their price objective on Aemetis from $2.50 to $2.20 and set a "buy" rating on the stock in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $13.43.

Aemetis Price Performance

NASDAQ:AMTX traded up $0.04 during trading hours on Friday, reaching $1.99. 1,161,716 shares of the company were exchanged, compared to its average volume of 754,832. The business has a 50 day moving average of $1.56 and a 200 day moving average of $2.14. The company has a market capitalization of $110.18 million, a P/E ratio of -0.88 and a beta of 1.48. Aemetis has a 1-year low of $1.22 and a 1-year high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.08). The company had revenue of $42.89 million during the quarter, compared to analyst estimates of $59.35 million. During the same period in the prior year, the company posted ($0.58) EPS. As a group, equities research analysts anticipate that Aemetis will post -2.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aemetis

Several hedge funds have recently modified their holdings of the company. ProShare Advisors LLC acquired a new position in Aemetis during the 4th quarter worth about $27,000. Voya Investment Management LLC acquired a new stake in shares of Aemetis in the fourth quarter valued at about $28,000. Tower Research Capital LLC TRC increased its stake in shares of Aemetis by 128.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock valued at $28,000 after buying an additional 5,859 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Aemetis in the fourth quarter valued at about $46,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Aemetis in the fourth quarter valued at about $87,000. Institutional investors and hedge funds own 27.02% of the company's stock.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.